Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou,Wanwisa Dejnirattisai,Piyada Supasa,Chang Liu,Alexander J Mentzer,Helen M Ginn,Yuguang Zhao,Helen M E Duyvesteyn,Aekkachai Tuekprakhon,Rungtiwa Nutalai,Beibei Wang,Guido C Paesen,Cesar Lopez-Camacho,Jose Slon-Campos,Bassam Hallis,Naomi Coombes,Kevin Bewley,Sue Charlton,Thomas S Walter,Donal Skelly,Sheila F Lumley,Christina Dold,Robert Levin,Tao Dong,Andrew J Pollard,Julian C Knight,Derrick Crook,Teresa Lambe,Elizabeth Clutterbuck,Sagida Bibi,Amy Flaxman,Mustapha Bittaye,Sandra Belij-Rammerstorfer,Sarah Gilbert,William James,Miles W Carroll,Paul Klenerman,Eleanor Barnes,Susanna J Dunachie,Elizabeth E Fry,Juthathip Mongkolsapaya,Jingshan Ren,David I Stuart,Gavin R Screaton

DOI: https://doi.org/10.1016/j.cell.2021.02.037

IF: 64.5

2021-04-29

Cell

Abstract:The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.